Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC)

Panelists discuss how the management of lung large cell neuroendocrine carcinoma (LCNEC) involves a multidisciplinary approach, focusing on molecular characterization, biomarker testing, and emerging treatment options, including novel targeted therapies and ongoing clinical trials.

EP. 1: Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

November 25th 2024

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.

EP. 2: An Overview of the Molecular Characterization of Lung LCNEC

November 25th 2024

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

EP. 3: The Pathological Diagnosis of Lung LCNEC

December 2nd 2024

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

EP. 4: Biomarker Testing Strategies for Lung LCNEC

December 2nd 2024

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.